Hepatic fibrosis: Are any of the serum markers useful?
- 1 February 2001
- journal article
- review article
- Published by Springer Nature in Current Gastroenterology Reports
- Vol. 3 (1) , 12-18
- https://doi.org/10.1007/s11894-001-0035-2
Abstract
No abstract availableKeywords
This publication has 52 references indexed in Scilit:
- Role of Transforming Growth Factor β Type Ii Receptor in Hepatic Fibrosis: Studies of Human Chronic Hepatitis C and Experimental Fibrosis in RatsHepatology, 1999
- Dual expression of matrix metalloproteinase-2 and membrane-type 1-matrix metalloproteinase in fibrotic human liversHepatology, 1997
- Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C: Relationship to interferon reponseJournal of Hepatology, 1997
- Serum Hyaluronan as a Disease MarkerAnnals of Medicine, 1996
- Serum markers of hepatic fibrogenesis in chronic hepatitis type C treated with alfa‐2A interferonLiver International, 1994
- Increased transforming growth factor-β1 gene expression in human liver diseaseJournal of Hepatology, 1992
- Serum type I collagen and N-terminal peptide of type III procollagen in chronic hepatitis: Relationship to liver histology and conventional liver testsJournal of Hepatology, 1991
- Is measurement of type III procollagen amino propeptide useful in primary biliary cirrhosis?Journal of Hepatology, 1989
- Serum aminoterminal type III procollagen peptide and the 7S domain of type IV collagen in patients with alcohol abuse Relation to ultrastructural fibrosis in the acinar zone 3 and to serum hyaluronanLiver International, 1987
- Persistent elevation of the aminoterminal peptide of procollagen type III in serum of patients with acute viral hepatitis distinguishes chronic active hepatitis from resolving or chronic persistent hepatitisJournal of Hepatology, 1986